• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl assists SpectraCure AB (publ) with preferential rights issue of units worth approximately MSEK 140

  • Home
  • Latest news
  • Cases and transactions
  • 2020
  • Lindahl assists SpectraCure AB (publ) with preferential rights issue of units worth approximately MSEK 140

Lindahl has acted as legal advisor to SpectraCure as it organises a preferential rights issue of units. SpectraCure intends to use the issue proceeds to fund, among other things, the preparations for and implementation of a phase 3 clinical study, regulatory preparations prior to an FDA application for accelerated approval, and the initiation of new clinical indications.

The subscription period for the rights issue ended on 23 June 2020 and resulted in the issue being fully subscribed to. 69.2 per cent of the units issued were subscribed to on the basis of unit rights, while 30.8 per cent were subscribed to without the support of unit rights, with 23 per cent of those subscribed to by investors in accordance with guarantee commitments. The issue will provide SpectraCure with approximately MSEK 140 before issue expenses.

Subscription to shares on the basis of the warrants will take place during September 2021. Upon full exercise of all warrants within the framework of issued units, SpectraCure may receive an additional MSEK 100 before issue expenses.

SpectraCure AB (publ), listed on the Nasdaq First North Premier Growth Market, is a medtech company which focuses on developing the treatment systems of the future for internal cancer tumours. The company has developed an advanced medical tool based on the IDOSE® software, packaged in the SpectraCure P18 instrument. The tool, together with associated disposable items, enables personalised treatment of internal solid tumours using photodynamic therapy (PDT).

Lindahl’s team consisted of Johan Herrström (responsible partner), Carl-Johan Krusell and Pontus Söderberg. G&W Fondkommission acted as the financial advisor.

 

Corporate finance

Lindahl's Corporate Finance team consists of 85 lawyers and is one of the largest in Sweden. Our solid experience and leading market position gives us the opportunity to participate in large projects with complex issues where we help clients to build an understanding of market conditions, challenges, opportunities and risks. We are top ranked in surveys based on client satisfaction and are constantly working to develop our consulting.

Visit page

Contact

  • Johan Herrström

    Malmö

    johan.herrstrom@lindahl.se +46 730 399 246
  • Carl-Johan Krusell

    Malmö

    carl-johan.krusell@lindahl.se +46 709 896 502
  • Pontus Söderberg

    Malmö

    pontus.soderberg@lindahl.se +46 723 571 422
Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm reception.stockholm@lindahl.se +46 8 527 70 800
  • Göteborg reception.goteborg@lindahl.se +46 31 799 10 00
  • Malmö reception.malmo@lindahl.se +46 40 664 66 50
  • Uppsala reception.uppsala@lindahl.se +46 18 16 18 50
  • Örebro reception.orebro@lindahl.se +46 19 20 89 00
  • Helsingborg reception.helsingborg@lindahl.se +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience